WO2002040665A3 - Complementing cell lines - Google Patents
Complementing cell lines Download PDFInfo
- Publication number
- WO2002040665A3 WO2002040665A3 PCT/NL2001/000824 NL0100824W WO0240665A3 WO 2002040665 A3 WO2002040665 A3 WO 2002040665A3 NL 0100824 W NL0100824 W NL 0100824W WO 0240665 A3 WO0240665 A3 WO 0240665A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell lines
- human
- adenovirus
- primary
- cell line
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ525997A NZ525997A (en) | 2000-11-15 | 2001-11-14 | Packaging cell lines for subgroup B recombinant adenoviruses |
AU2002218569A AU2002218569B2 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
AU1856902A AU1856902A (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
CA2428739A CA2428739C (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
DE60121471T DE60121471T2 (en) | 2000-11-15 | 2001-11-14 | COMPLEMENTING CELL LINES |
SI200130627T SI1349926T1 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
EP01996603A EP1349926B1 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
JP2002543660A JP4402881B2 (en) | 2000-11-15 | 2001-11-14 | Complementary cell lines |
CY20061101321T CY1105232T1 (en) | 2000-11-15 | 2006-09-15 | COMPLEMENTATION CELL LINES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/713,678 | 2000-11-15 | ||
US09/713,678 US6492169B1 (en) | 1999-05-18 | 2000-11-15 | Complementing cell lines |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002040665A2 WO2002040665A2 (en) | 2002-05-23 |
WO2002040665A3 true WO2002040665A3 (en) | 2002-10-17 |
Family
ID=24867049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2001/000824 WO2002040665A2 (en) | 2000-11-15 | 2001-11-14 | Complementing cell lines |
Country Status (13)
Country | Link |
---|---|
US (8) | US6492169B1 (en) |
EP (1) | EP1349926B1 (en) |
JP (1) | JP4402881B2 (en) |
AT (1) | ATE332965T1 (en) |
AU (2) | AU2002218569B2 (en) |
CA (1) | CA2428739C (en) |
CY (1) | CY1105232T1 (en) |
DE (1) | DE60121471T2 (en) |
DK (1) | DK1349926T3 (en) |
ES (1) | ES2267864T3 (en) |
NZ (1) | NZ525997A (en) |
PT (1) | PT1349926E (en) |
WO (1) | WO2002040665A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
CA2222140C (en) * | 1995-06-15 | 2010-11-23 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
US7604960B2 (en) * | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) * | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
CA2421864A1 (en) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
DE60138403D1 (en) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST |
ES2297028T3 (en) * | 2001-12-07 | 2008-05-01 | Crucell Holland B.V. | PRODUCTION OF VIRUSES, ISOLATED VIRALS AND VACCINES. |
DE60329835D1 (en) * | 2002-04-25 | 2009-12-10 | Crucell Holland Bv | MEDIUM AND METHOD FOR THE PRODUCTION OF ADENOVIRUS VECTORS |
JP4495588B2 (en) * | 2002-04-25 | 2010-07-07 | クルセル ホランド ベー ヴェー | Stable adenoviral vector and method for propagation thereof |
US20060073123A1 (en) * | 2002-04-30 | 2006-04-06 | Jie Mi | Adenovirus vectors for immunotherapy |
JP4237449B2 (en) * | 2002-06-05 | 2009-03-11 | 国立医薬品食品衛生研究所長 | Adenovirus vector |
US20080153083A1 (en) * | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
WO2004037294A2 (en) | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
US9388427B2 (en) * | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
NZ539813A (en) | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
JP2006521089A (en) * | 2003-03-28 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | Adenovirus serotype 34 vector, nucleic acid and virus produced thereby |
WO2004099396A1 (en) | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
ATE469920T1 (en) * | 2003-05-23 | 2010-06-15 | Crucell Holland Bv | PRODUCTION OF RECOMBINANT IGM IN THE PER.C6 CELLS |
CN1934253A (en) * | 2003-07-18 | 2007-03-21 | 昂尼克斯药物公司 | Subgroup B adenoviral vectors for treating disease |
ES2359473T3 (en) | 2003-07-21 | 2011-05-23 | Transgene S.A. | MULTIFUNCTIONAL CYTOKINS. |
EA010924B1 (en) * | 2003-10-02 | 2008-12-30 | Круселл Холланд Б.В. | Method for generating a batch of recombinant adenovirus and packaging cells used therefor |
AU2005214090B2 (en) * | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
JP4896021B2 (en) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Alphavirus vector for respiratory pathogen vaccine |
US7537930B2 (en) | 2004-07-23 | 2009-05-26 | Immunomedics, Inc. | Mammalian cell lines for increasing longevity and protein yield from a cell culture |
US7608425B2 (en) | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
US7531327B2 (en) | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
EA010433B1 (en) | 2004-10-13 | 2008-08-29 | Круселл Холланд Б.В. | Improved adenoviral vectors and uses thereof |
EP1812580B1 (en) | 2004-11-16 | 2014-12-17 | Crucell Holland B.V. | Multivalent vaccines comprising recombinant viral vectors |
WO2006063053A2 (en) | 2004-12-08 | 2006-06-15 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
AU2012216357B2 (en) * | 2005-04-11 | 2014-01-30 | Purdue Research Foundation | Vaccine against pandemic strains of influenza viruses |
CA2602944C (en) * | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
EP1899470A4 (en) * | 2005-05-23 | 2009-07-29 | Vaxin Inc | System for rapid production of high-titer and replication-competent adenovirus-free recombinant adenovirus vectors |
AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
CN101365480B (en) | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
DE102005054628A1 (en) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Process for the preparation of permanent human cell lines |
US20100143302A1 (en) * | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
CN101472941B (en) | 2006-03-31 | 2017-08-08 | 沃弗-威斯康星校友研究基金会 | High titer recombinant influenza viruses for vaccine |
ES2396915T3 (en) | 2006-06-02 | 2013-03-01 | International Aids Vaccine Initiative | Consensus sequences, antigens and transgenes of HIV-1 of clade A |
EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
BRPI0806350A2 (en) | 2007-01-30 | 2011-09-06 | Transgene Sa | use of a nucleic acid molecule, use of a vector, use of an infectious viral particle, vectors, infectious viral particle and composition |
EP2132300B1 (en) * | 2007-03-09 | 2011-01-12 | Vectorlogics, Inc. | Cells for adenovirus vector and protein production |
WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
US8871515B2 (en) | 2008-09-17 | 2014-10-28 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
EP2350268B1 (en) * | 2008-11-03 | 2014-12-24 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
BRPI1006901A2 (en) | 2009-01-20 | 2016-02-16 | Transgène S A | ex vivo method and kit for testing if a patient will respond therapeutically to a treatment method, and use of sicam-1 levels in a blood sample |
SG174507A1 (en) | 2009-03-24 | 2011-10-28 | Transgene Sa | Biomarker for monitoring patients |
WO2010119003A1 (en) | 2009-04-17 | 2010-10-21 | Transgene Sa | Biomarker for monitoring patients |
DK2452194T3 (en) | 2009-07-10 | 2015-11-30 | Transgene Sa | Biomarker PATIENT SELECTION AND RELATED PRACTICES |
NZ598000A (en) | 2009-08-07 | 2013-10-25 | Transgene Sa | Composition for treating hbv infection |
WO2011045378A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
KR101805938B1 (en) | 2009-10-15 | 2018-01-10 | 얀센 백신스 앤드 프리벤션 비.브이. | Process for adenovirus purification from high cell density cultures |
ES2813347T3 (en) | 2009-10-26 | 2021-03-23 | Wisconsin Alumni Res Found | Recombinant High Titer Influenza Viruses with Enhanced Replication in Vero Cells |
EP2531592A1 (en) | 2010-02-04 | 2012-12-12 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
MX2012007936A (en) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Method for the production of ad26 adenoviral vectors. |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US20130203151A1 (en) | 2010-04-26 | 2013-08-08 | Scott Balsitis | Production of alphavirus replicon particles in packaging cells |
TW201211257A (en) * | 2010-08-16 | 2012-03-16 | Cevec Pharmaceuticals Gmbh | Permanent human cell line for influenza virus preparation |
EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
ES2716243T3 (en) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Antigen Supply Platforms |
EP4159232A1 (en) | 2011-01-26 | 2023-04-05 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
US9058175B2 (en) * | 2011-06-07 | 2015-06-16 | The Mathworks, Inc. | Parameter promotion in a block diagram modeling environment |
US20140271829A1 (en) | 2011-10-11 | 2014-09-18 | Anders Lilja | Recombinant self-replicating polycistronic rna molecules |
US20140348863A1 (en) | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
CA2857087C (en) | 2011-11-28 | 2021-05-25 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
AU2013231423B2 (en) | 2012-03-12 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Batches of recombinant adenovirus with altered terminal ends |
KR102023791B1 (en) | 2012-03-22 | 2019-09-23 | 얀센 백신스 앤드 프리벤션 비.브이. | Vaccine against rsv |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
US9442702B1 (en) | 2012-04-30 | 2016-09-13 | The Mathworks, Inc. | Overriding an interface in a graphical block diagram modeling environment |
US9476061B2 (en) | 2012-05-24 | 2016-10-25 | Janssen Vaccines & Prevention B.V. | Adenoviral vectors for transduction of vascular tissue |
JP6430949B2 (en) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Conjugates, compositions, and related methods of GM-CSF and IL-4 |
CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
EA039803B1 (en) | 2013-04-25 | 2022-03-15 | Янссен Вэксинс Энд Превеншн Б.В. | Stabilized soluble prefusion rsv f polypeptides |
BR112015031509B1 (en) | 2013-06-17 | 2023-05-09 | Janssen Vaccines & Prevention B.V. | RESPIRATORY SYNCYTIAL VIRUS (RSV) FUSION POLYPEPTIDE (F) RECOMBINANT PRE-FUSION AND COMPOSITION INCLUDING IT |
EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
EP3046536B1 (en) | 2013-09-19 | 2018-11-28 | Janssen Vaccines & Prevention B.V. | Improved adenovirus formulations |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
AR102547A1 (en) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE |
AR102548A1 (en) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
US20180271891A1 (en) | 2015-03-11 | 2018-09-27 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
CA2981841A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
JP6913032B2 (en) | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | Common neoantigen |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
TW202241500A (en) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | Formulations for neoplasia vaccines and methods of preparing thereof |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
EP3821906A1 (en) | 2015-07-07 | 2021-05-19 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv comprising modified f polypeptide |
JP6487604B2 (en) | 2015-10-06 | 2019-03-20 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Methods for preventing plastic-induced degradation of biological agents |
JP2019510481A (en) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | Improved influenza B virus replication for vaccine development |
IL262109B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Vaccine against rsv |
SI3439672T1 (en) | 2016-04-05 | 2021-02-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection |
EP3446119A1 (en) | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
DK3464331T3 (en) | 2016-05-30 | 2021-01-18 | Janssen Vaccines & Prevention Bv | STABILIZED PREFUSION RSV F PROTEINS |
JP6683847B2 (en) | 2016-06-20 | 2020-04-22 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Strong and balanced bidirectional promoter |
JP7229151B2 (en) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | HPV vaccine |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US20200096521A1 (en) | 2017-02-12 | 2020-03-26 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
JP7295124B2 (en) | 2017-11-03 | 2023-06-20 | タケダ ワクチン,インコーポレイテッド | Zika vaccines and immunogenic compositions and methods of use thereof |
US11773142B2 (en) | 2017-12-11 | 2023-10-03 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
TW201930340A (en) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | Neoantigens and uses thereof |
CN108342362A (en) * | 2018-01-31 | 2018-07-31 | 武汉枢密脑科学技术有限公司 | A kind of stable cell lines MDCK and its construction method for expanding recombination hepatitis infectiosa canis virus CAV2 |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
KR20210130705A (en) | 2018-12-21 | 2021-11-01 | 바이오엔테크 유에스 인크. | Methods and systems for HLA class II-specific epitope prediction and CD4+ T cell characterization |
US11241492B2 (en) | 2019-01-23 | 2022-02-08 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to genes in influenza viruses |
JP2022522112A (en) | 2019-02-08 | 2022-04-14 | ウィスコンシン アルムニ リサーチ ファンデイション | Humanized cell line |
CN114929269A (en) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | Improved influenza virus replication for vaccine development |
AU2020269164B2 (en) | 2019-05-08 | 2024-04-04 | Takeda Vaccines, Inc. | Inactivated virus compositions and Zika vaccine formulations |
CN113950333A (en) | 2019-05-15 | 2022-01-18 | 扬森疫苗与预防公司 | Prophylactic treatment of respiratory syncytial virus infection using adenovirus-based vaccines |
CN113924113A (en) | 2019-05-15 | 2022-01-11 | 扬森疫苗与预防公司 | Co-administration of seasonal influenza vaccine with adenovirus-based respiratory syncytial virus vaccine |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
EP4259206A2 (en) | 2020-12-14 | 2023-10-18 | BioNTech US Inc. | Tissue-specific antigens for cancer immunotherapy |
WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
WO2023239928A1 (en) * | 2022-06-09 | 2023-12-14 | CHO Plus Inc. | Cell hybrids as host cells for high efficiency production of gene therapy vectors and viral vaccines |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000326A1 (en) * | 1995-06-15 | 1997-01-03 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
WO1998017783A1 (en) * | 1996-10-23 | 1998-04-30 | Regents Of The University Of Michigan | Improved adenovirus vectors |
US5880102A (en) * | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
DE19754103A1 (en) * | 1997-12-08 | 1999-06-10 | Hepavec Ag Fuer Gentherapie | New packaging cell line for E1-deleted adenovirus |
WO1999032647A1 (en) * | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
DE19807265A1 (en) * | 1998-02-20 | 1999-08-26 | Centeon Pharma Gmbh | New adenoviral vector useful for gene therapy |
DE19918023A1 (en) * | 1999-03-16 | 2000-09-21 | Guenter Cichon | Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) * | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4517686A (en) * | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) * | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
FR2602790B1 (en) | 1986-08-13 | 1990-06-01 | Transgene Sa | EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2000048A1 (en) * | 1988-10-03 | 1990-04-03 | Edward F. Plow | Peptides and antibodies that inhibit integrin-ligand bindin g |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5223394A (en) * | 1989-04-10 | 1993-06-29 | Biogen, Inc. | Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
WO1991005805A1 (en) | 1989-10-20 | 1991-05-02 | Trustees Of Dartmouth College | MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR |
DK0595798T3 (en) | 1989-10-20 | 1999-09-27 | Medarex Inc | Bispecific hetero antibodies with dual effector functions |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
GB2246779B (en) | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
GB9101550D0 (en) | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
ATE237694T1 (en) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT |
FR2681786A1 (en) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS. |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
EP0669987B1 (en) | 1992-09-25 | 2008-08-13 | Aventis Pharma S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
ATE307212T1 (en) | 1992-11-18 | 2005-11-15 | Arch Dev Corp | ADENOVIRUS-DIRECTED GENE TRANSFER TO THE HEART AND VASCULAR SMOOTH MUSCLE |
GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
AU6133394A (en) | 1993-02-09 | 1994-08-29 | Scripps Research Institute, The | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
DE4311651A1 (en) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
PT698109E (en) | 1993-05-10 | 2002-12-31 | Univ Michigan | TRANSFER OF GENES INTO PANCREATIC EPITHELIAL CELLS |
US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
EP0716711A1 (en) | 1993-09-03 | 1996-06-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Vector for gene therapy of the liver |
US5552311A (en) * | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5534423A (en) * | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
FR2712812B1 (en) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition for the production of therapeutic products in vivo. |
IT1271461B (en) | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE. |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
EP0759087B1 (en) | 1994-05-13 | 2001-03-28 | Chiron Corporation | Compositions and methods for targeting gene delivery vehicles |
US5571531A (en) | 1994-05-18 | 1996-11-05 | Mcmaster University | Microparticle delivery system with a functionalized silicone bonded to the matrix |
US5570975A (en) | 1994-06-27 | 1996-11-05 | Reinert, Sr.; Gary L. | Metal foundation push-it and installation apparatus and method |
FR2721943B1 (en) | 1994-06-29 | 1996-08-02 | Rhone Poulenc Rorer Sa | ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
AU705595B2 (en) | 1994-09-09 | 1999-05-27 | Neurocrine Biosciences, Incorporated | Interleukin-1 type 3 receptors |
FR2724846B1 (en) | 1994-09-27 | 1996-12-20 | Rhone Poulenc Rorer Sa | METHOD OF TREATING CANCER BY REGULATING THE ACTIVITY OF RAS PROTEINS |
FR2725726B1 (en) * | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | VIRAL VECTORS AND USE IN GENE THERAPY |
US6001557A (en) | 1994-10-28 | 1999-12-14 | The Trustees Of The University Of Pennsylvania | Adenovirus and methods of use thereof |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996014837A1 (en) | 1994-11-09 | 1996-05-23 | Genetic Therapy, Inc. | Gene therapy for hypercholesterolemia |
AU3993495A (en) | 1994-11-29 | 1996-06-19 | Takara Shuzo Co., Ltd. | Process for producing transformed cell |
FR2727867B1 (en) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS |
AUPN107195A0 (en) | 1995-02-10 | 1995-03-09 | Withers, Graham Rex | Metal matrix forming method and apparatus |
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
CA2218808A1 (en) | 1995-05-10 | 1996-11-14 | Introgene B.V. | Improved retroviral vectors, especially suitable for gene therapy |
US6265212B1 (en) * | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
JP2001520511A (en) | 1995-12-08 | 2001-10-30 | ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション | Targeting adenovirus vector |
EP0927044A4 (en) | 1996-04-16 | 1999-09-08 | Immusol Inc | Targeted viral vectors |
US6210921B1 (en) | 1996-09-13 | 2001-04-03 | Robert W. Finberg | CAR: a novel coxsackievirus and adenovirus receptor |
NZ508399A (en) | 1996-09-25 | 2003-06-30 | Novartis Ag | Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
DE69830320T2 (en) * | 1997-03-07 | 2006-02-02 | The Wistar Institute Of Anatomy And Biology | Use of adenoviral vectors expressing PDGF or VEGF for the healing of tissue defects and for the induction of hypervascularism in mastoid tissues |
US6100086A (en) * | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
AU7250298A (en) | 1997-04-25 | 1998-11-24 | Collateral Therapeutics, Inc. | Truncated vegf-related proteins |
EP1015005A4 (en) | 1997-05-08 | 2002-10-16 | Genetic Therapy Inc | Gene transfer with adenoviruses having modified fiber proteins |
US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
US6287857B1 (en) * | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
AU3358999A (en) | 1998-03-20 | 1999-10-11 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
IT1299201B1 (en) | 1998-05-08 | 2000-02-29 | San Raffaele Centro Fond | GENETICALLY MODIFIED FIBROBLASTS AND THEIR USE |
EP0959136A1 (en) | 1998-05-20 | 1999-11-24 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
WO2000024730A1 (en) | 1998-10-28 | 2000-05-04 | The University Of British Columbia | Organic vanadium(iii) complexes and their use |
EP1020529B1 (en) | 1998-11-20 | 2005-06-01 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
IL133032A (en) | 1998-11-20 | 2007-06-03 | Introgene Bv | Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
EP1016726A1 (en) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
JP4683727B2 (en) | 1999-03-04 | 2011-05-18 | クルーセル ホランド ベスローテン フェンノートシャップ | Means and methods for transduction of fibroblast-like or macrophage-like cells |
US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
DK1816204T3 (en) | 1999-05-17 | 2011-01-24 | Crucell Holland Bv | Recombinant adenovirus of the Ad26 serotype |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
WO2001030158A1 (en) | 1999-10-28 | 2001-05-03 | Research Association For Improvement Of Wood Quality | Creosote oil emulsion and process for producing the same |
ES2256302T3 (en) | 2000-08-10 | 2006-07-16 | Crucell Holland B.V. | ADENOVIRAL VECTORS FOR THE TRANSDUCTION OF CONDROCITS. |
CA2421864A1 (en) | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
DE60138403D1 (en) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST |
EP1191104A1 (en) | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
US6905678B2 (en) | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
JP4495588B2 (en) | 2002-04-25 | 2010-07-07 | クルセル ホランド ベー ヴェー | Stable adenoviral vector and method for propagation thereof |
DE60329835D1 (en) | 2002-04-25 | 2009-12-10 | Crucell Holland Bv | MEDIUM AND METHOD FOR THE PRODUCTION OF ADENOVIRUS VECTORS |
WO2004037294A2 (en) | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
US7026164B2 (en) * | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
EA010924B1 (en) | 2003-10-02 | 2008-12-30 | Круселл Холланд Б.В. | Method for generating a batch of recombinant adenovirus and packaging cells used therefor |
EA010433B1 (en) | 2004-10-13 | 2008-08-29 | Круселл Холланд Б.В. | Improved adenoviral vectors and uses thereof |
EP1812580B1 (en) | 2004-11-16 | 2014-12-17 | Crucell Holland B.V. | Multivalent vaccines comprising recombinant viral vectors |
-
2000
- 2000-11-15 US US09/713,678 patent/US6492169B1/en not_active Expired - Lifetime
-
2001
- 2001-11-14 EP EP01996603A patent/EP1349926B1/en not_active Expired - Lifetime
- 2001-11-14 ES ES01996603T patent/ES2267864T3/en not_active Expired - Lifetime
- 2001-11-14 JP JP2002543660A patent/JP4402881B2/en not_active Expired - Lifetime
- 2001-11-14 DE DE60121471T patent/DE60121471T2/en not_active Expired - Lifetime
- 2001-11-14 AT AT01996603T patent/ATE332965T1/en active
- 2001-11-14 AU AU2002218569A patent/AU2002218569B2/en not_active Ceased
- 2001-11-14 WO PCT/NL2001/000824 patent/WO2002040665A2/en active IP Right Grant
- 2001-11-14 PT PT01996603T patent/PT1349926E/en unknown
- 2001-11-14 NZ NZ525997A patent/NZ525997A/en not_active IP Right Cessation
- 2001-11-14 DK DK01996603T patent/DK1349926T3/en active
- 2001-11-14 CA CA2428739A patent/CA2428739C/en not_active Expired - Fee Related
- 2001-11-14 AU AU1856902A patent/AU1856902A/en active Pending
- 2001-11-15 US US10/002,750 patent/US6974695B2/en not_active Expired - Lifetime
-
2002
- 2002-06-04 US US10/164,085 patent/US6869794B2/en not_active Expired - Lifetime
- 2002-10-15 US US10/272,041 patent/US7250293B2/en not_active Expired - Lifetime
-
2005
- 2005-06-24 US US11/165,697 patent/US7344883B2/en not_active Expired - Lifetime
-
2006
- 2006-09-15 CY CY20061101321T patent/CY1105232T1/en unknown
-
2007
- 2007-04-11 US US11/786,409 patent/US20080199433A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,806 patent/US20130156736A1/en not_active Abandoned
-
2014
- 2014-07-18 US US14/335,679 patent/US9228205B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880102A (en) * | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
WO1997000326A1 (en) * | 1995-06-15 | 1997-01-03 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
WO1998017783A1 (en) * | 1996-10-23 | 1998-04-30 | Regents Of The University Of Michigan | Improved adenovirus vectors |
DE19754103A1 (en) * | 1997-12-08 | 1999-06-10 | Hepavec Ag Fuer Gentherapie | New packaging cell line for E1-deleted adenovirus |
WO1999032647A1 (en) * | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
DE19807265A1 (en) * | 1998-02-20 | 1999-08-26 | Centeon Pharma Gmbh | New adenoviral vector useful for gene therapy |
DE19918023A1 (en) * | 1999-03-16 | 2000-09-21 | Guenter Cichon | Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells |
Non-Patent Citations (2)
Title |
---|
RUMPF H ET AL: "Two domains within the adenovirus type 12 E1A unique spacer have disparate effects on the interaction of E1A with P105- Rb and the transformation of primary mouse cells", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 257, no. 1, 25 April 1999 (1999-04-25), pages 45 - 53, XP002134555, ISSN: 0042-6822 * |
SCHIEDNER G ET AL: "EFFICIENT TRANSFORMATION OF PRIMARY HUMAN AMNIOCYTES BY E1 FUNCTIONS OF AD5: GENERATION OF NEW CELL LINES FOR ADENOVIRAL VECTOR PRODUCTION", HUMAN GENE THERAPY, XX, XX, vol. 11, no. 15, 10 October 2000 (2000-10-10), pages 2105 - 2116, XP000974022, ISSN: 1043-0342 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
Also Published As
Publication number | Publication date |
---|---|
US20030171336A1 (en) | 2003-09-11 |
US20050277194A1 (en) | 2005-12-15 |
US20150010952A1 (en) | 2015-01-08 |
JP4402881B2 (en) | 2010-01-20 |
US20030185801A1 (en) | 2003-10-02 |
CA2428739C (en) | 2010-11-16 |
CY1105232T1 (en) | 2010-03-03 |
US20080199433A1 (en) | 2008-08-21 |
US20130156736A1 (en) | 2013-06-20 |
ATE332965T1 (en) | 2006-08-15 |
DE60121471D1 (en) | 2006-08-24 |
US6974695B2 (en) | 2005-12-13 |
PT1349926E (en) | 2006-12-29 |
EP1349926A2 (en) | 2003-10-08 |
US6492169B1 (en) | 2002-12-10 |
DK1349926T3 (en) | 2006-10-30 |
US20030119192A1 (en) | 2003-06-26 |
JP2004513657A (en) | 2004-05-13 |
WO2002040665A2 (en) | 2002-05-23 |
US6869794B2 (en) | 2005-03-22 |
NZ525997A (en) | 2005-10-28 |
EP1349926B1 (en) | 2006-07-12 |
US7250293B2 (en) | 2007-07-31 |
DE60121471T2 (en) | 2007-02-08 |
AU1856902A (en) | 2002-05-27 |
AU2002218569B2 (en) | 2007-04-05 |
ES2267864T3 (en) | 2007-03-16 |
US7344883B2 (en) | 2008-03-18 |
CA2428739A1 (en) | 2002-05-23 |
US9228205B2 (en) | 2016-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002040665A3 (en) | Complementing cell lines | |
Gao et al. | State‐of‐the‐art human adenovirus vectorology for therapeutic approaches | |
Schiedner et al. | Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production | |
Croyle et al. | “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung | |
Eto et al. | PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability | |
Fallaux et al. | New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses | |
CA2477954A1 (en) | Means and methods for the production of adenovirus vectors | |
Randrianarison-Jewtoukoff et al. | Recombinant adenoviruses as vaccines | |
Vogels et al. | Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity | |
Von Seggern et al. | A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles | |
EP2903600B1 (en) | Virus-containing formulation and use thereof | |
Barouch | Rational design of gene‐based vaccines | |
WO2000012740A3 (en) | Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences | |
CA2161962A1 (en) | Adenovirus vectors for gene therapy | |
AU5152998A (en) | Improved adenovirus vectors | |
WO2003078592A3 (en) | Method for the purification, production and formulation of oncolytic adenoviruses | |
JP2005523730A5 (en) | ||
NO20010576L (en) | Immunological herpes simplex virus antigens and methods for their use | |
WO2005103272A2 (en) | Pan cancer oncolytic vectors and methods of use thereof | |
WO2003047617A3 (en) | Vaccine | |
WO2008095027A3 (en) | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene | |
Fattori et al. | Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes | |
AU2002337083A1 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
WO2001055362A3 (en) | Hybrid adeno-retroviral vector for the transfection of cells | |
WO2001021201A3 (en) | Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001996603 Country of ref document: EP Ref document number: 2428739 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002543660 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 525997 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002218569 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001996603 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 525997 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525997 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001996603 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002218569 Country of ref document: AU |